Twenty-nine consecutive years of dividend growth is a claim almost no London-listed company can make, which is exactly why Primary Health Properties (PHP:LSE) occupies a special place in the affections of UK income-focused observers. The healthcare landlord’s distribution record — extended, according to the company, through nearly three decades of rate cycles, recessions and a pandemic — now sits alongside a trailing yield of roughly 7.37% on recent market data.

That combination of record and yield reflects a business genuinely transformed. In August 2025, PHP completed its £1.6 billion acquisition of rival Assura, a deal cleared by the Competition and Markets Authority that October, creating a portfolio of around £6 billion spanning 1,142 healthcare properties across the UK and Ireland.

The enlarged group’s operating metrics read like a defensive checklist: occupancy of about 99%, a weighted average unexpired lease term of 10.8 years, and rents overwhelmingly funded, directly or indirectly, by the NHS and its Irish counterpart.

The catch, and the reason the yield sits as high as it does, is on the liabilities side. The Assura deal lifted PHP’s loan-to-value ratio to around 57%, well above the sector’s comfort zone, with the company targeting a reduction through disposals and synergies during 2026. How that deleveraging progresses may define the stock’s next chapter.

The NHS as Anchor Tenant: Inside PHP’s Enlarged Portfolio

Primary Health Properties is a FTSE-listed UK real estate investment trust, trading under the ticker PHP, that owns modern primary healthcare premises — chiefly GP surgeries, health centres and primary care facilities — let on long leases and funded largely by government health bodies. It’s among the most specialised of the major London-listed REITs, and deliberately so.

The business model’s foundations are genuinely unusual in commercial property. The majority of PHP’s rent roll is effectively backed by the NHS in the UK and the HSE in Ireland, since GP practices’ premises costs are reimbursed by the state. Tenants rarely leave — a purpose-built surgery has few alternative occupiers, and healthcare demand doesn’t fluctuate with the economic cycle — which explains occupancy holding around 99% and lease terms averaging more than a decade.

The Assura combination reshaped the company’s scale entirely. Completed in August 2025 after a competitive bid process and confirmed by CMA clearance in October 2025, the £1.6 billion transaction brought together the sector’s two dominant specialists into a portfolio of 1,142 assets worth approximately £6 billion. PHP has said the integration is running ahead of schedule, with more than 80% of targeted cost synergies already delivered by mid-2026, according to company updates.

Scale brings advantages the company has been keen to emphasise: a lower combined cost ratio, deeper relationships with health commissioners, and a stronger platform for funding the modern, larger premises that health systems increasingly demand.

Rental growth, historically the model’s soft spot, has been improving too. A rising share of PHP’s leases carry index-linked or fixed uplifts, and open-market rent reviews have been benefiting from the higher construction costs that make new surgeries more expensive to replace — a dynamic the company has described as supportive of reversionary growth across the estate.

Healthcare Property and the Defensive Income Trade

The investment logic for healthcare real estate rests on demographics and government policy rather than GDP growth. The UK’s population is ageing, demand for primary care continues to climb, and successive governments have pledged to shift care from hospitals into community settings — a policy direction reaffirmed in NHS planning documents that PHP has repeatedly cited as underpinning long-term demand for its premises.

Against the wider property market, that gives the sector a distinctive profile. While offices wrestle with hybrid working and retail with structural change, primary care premises face no equivalent obsolescence debate; the question is whether the state funds enough new capacity, not whether the buildings themselves are needed.

For income-focused observers, the comparison that matters is with bonds. PHP’s long, government-backed income stream behaves somewhat like an index-flavoured gilt with property risk attached, which made the shares acutely sensitive to the 2022–23 rate shock: as gilt yields surged, the stock de-rated sharply along with the wider UK real estate universe. With the Bank of England base rate at 3.75% by mid-2026 and markets pricing gradual easing toward 3.5%, the arithmetic has been slowly turning friendlier. The 10-year gilt around 4.3% still offers competition, but a 7%-plus yield from near-full occupancy assets prices in considerable scepticism.

That scepticism concentrates squarely on leverage. A 57% loan-to-value ratio is high for the sector, where large REITs typically target 30–40%, and it magnifies both valuation moves and refinancing costs. PHP has set out a path to bring gearing down through selective disposals — assets identified from the combined portfolio — alongside synergy delivery and retained earnings. Progress against that plan is likely to be treated as the stock’s key performance test through 2026.

Why Primary Health Properties Still Draws Income-Focused Attention

The dividend record is the headline story. PHP’s claim of around 29 consecutive years of distribution growth stands almost alone among LSE property shares, and the board extended the streak through the Assura integration period — a statement of confidence in the enlarged group’s cash flows. For anyone following real estate income names, few UK dividend stocks offer a comparable history.

Income quality is the second attraction. Rents funded by government health systems, 99% occupancy and a 10.8-year average lease term add up to arguably the most secure rent roll in mainstream UK property. Tenant default risk, the perennial anxiety of commercial landlords, is minimal by construction here.

The synergy story adds near-term earnings support. With over 80% of targeted savings reported as delivered, the company has visible, self-controlled earnings drivers that don’t depend on market conditions — useful ballast while rate expectations continue to evolve.

There’s also a valuation angle worth noting: a yield of 7.37% from assets of this security implies either that the market doubts the dividend, or that it’s charging heavily for the balance sheet’s leverage. A broadly constructive tone among analysts suggests the professional community leans toward the second interpretation while still demanding visible deleveraging progress. Sentiment can shift, of course, but the framing explains why the shares feature so prominently in defensive-income discussions.

The counterpoints — leverage, rate sensitivity and modest historic rental growth — are addressed in full below, and none of them is trivial.

Key Metrics Worth Tracking

• Loan-to-value trajectory — the reduction of gearing from around 57% via disposals and retained earnings is the central plank of the post-Assura plan; each results statement will be judged against it.

• Disposal execution — the pricing achieved on asset sales relative to book value will show whether deleveraging can proceed without eroding NAV.

• Synergy completion — delivering the remainder of the targeted cost savings would cement the earnings case for the merger.

• Dividend cover — whether earnings comfortably fund the progressive dividend, especially during the deleveraging phase, underpins the 29-year growth record’s continuation.

• Rent review outcomes — index-linked uplifts and open-market reviews determine organic income growth across the 1,142-asset portfolio.

• Government health policy — NHS capital programmes and any shift in premises reimbursement arrangements shape long-term demand and rental settings.

• Interest rates and refinancing — the cost of debt on a large, geared balance sheet moves with the rate cycle; easing toward 3.5% would help, persistence at higher levels would hurt.

Risks Worth Weighing

PHP’s risk profile is unusual: operational risks are slight, financial risks are not.

Leverage dominates the picture. At around 57% loan-to-value, the balance sheet carries roughly half as much again of the gearing large REITs typically run. If healthcare property values were to fall — under renewed rate pressure, for instance — the LTV would rise mechanically, potentially constraining dividends, forcing accelerated disposals or, in adverse scenarios, testing covenant headroom. The company’s deleveraging plan addresses this, but plans require execution and cooperative markets.

Interest-rate sensitivity follows directly from that. Long-lease, bond-like income makes the shares trade with gilt yields; a resurgence of inflation or a stalled easing cycle could reopen the de-rating seen in 2022–23, whatever the operational performance looks like.

Political and policy risk deserves respect, too. PHP’s income depends on government reimbursement structures that could change, and rent settlements with health bodies involve negotiation with a monopsony customer. Policy support for community care is longstanding, but funding for new premises has repeatedly moved slower than the rhetoric around it.

Integration risk has diminished as synergies land, though the tail of combining two large platforms — systems, teams, disposals of overlapping assets — still carries execution demands.

Finally, growth expectations should stay modest. Healthcare rents grow steadily rather than excitingly, and with a large asset base, transformative expansion is unlikely — this is an income compounder, not a growth stock, and any dividend depends on board decisions rather than guarantees.

Outlook: Deleveraging Could Set the Narrative

The next several reporting periods may be read through a single lens: does the loan-to-value ratio fall as promised? Successful disposals at sensible prices, completed synergies and a covered, still-growing dividend could allow attention to refocus on PHP’s core proposition — government-backed income with inflation-flavoured growth — and the yield could then be reassessed against easing gilt rates.

If deleveraging lags or asset values soften, the balance-sheet discount may persist and the dividend streak could come under closer scrutiny. Rate expectations remain the swing factor worth watching most closely: gradual easing toward 3.5% would flatter every part of the equation, while sticky inflation would test it.

Neither path is assured, and the company’s own guidance — disposals, synergy completion, LTV reduction through 2026 — provides the measurable milestones against which the story may be judged.

Conclusion

Primary Health Properties emerges from the Assura acquisition as the undisputed specialist consolidator of UK and Irish primary care premises: £6 billion of assets, 99% occupancy, decade-long leases and a rent roll anchored by the state. Layered on top is one of the London market’s great income records — nearly three decades of dividend growth — and a yield above 7% that reflects the balance sheet assembled to build it.

The stock’s dual identity is the whole story: operationally among the most defensive of UK REITs, financially among the more geared. For income-focused observers, PHP in 2026 is a genuine test of whether disciplined deleveraging can reunite those two identities — and the milestones, unusually, are all published in advance.